AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
5.40
+0.40 (8.00%)
Jun 22, 2026, 4:00 PM EDT - Market closed

AN2 Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
1943141609185-
Market Cap Growth
491.30%-24.31%-93.23%229.57%--
Enterprise Value
109.2-26.75-42.33502.1188.90
Last Close Price
5.401.141.3820.499.53-
PB Ratio
2.380.590.504.891.94-
P/TBV Ratio
2.060.650.503.881.53-
EV/EBITDA Ratio
-0.700.75---
EV/EBIT Ratio
-0.700.75---
EV/FCF Ratio
-0.900.86---
Net Debt / Equity Ratio
-1.04-1.09-1.02-0.86-1.011.24
Net Debt / EBITDA Ratio
2.301.521.471.542.272.71
Net Debt / FCF Ratio
2.731.941.702.012.872.86
Quick Ratio
15.336.658.177.6413.3717.25
Current Ratio
15.736.878.437.8713.7217.70
Return on Equity (ROE)
-51.26%-52.14%-49.69%-58.83%-40.02%-32.55%
Return on Assets (ROA)
-49.68%-49.48%-49.20%-57.72%-50.35%-62.04%
Return on Invested Capital (ROIC)
-1949.23%-773.16%-319.74%-423.27%-916.25%-823.28%
Return on Capital Employed (ROCE)
-54.93%-56.42%-54.99%-63.28%-53.74%-66.69%
Buyback Yield / Dilution
-4.40%-1.30%-26.39%-53.85%-481.46%-2.71%
Total Shareholder Return
-4.40%-1.30%-26.39%-53.85%-481.46%-2.71%
SEC Filings: 10-K · 10-Q